ASX Share rice
Sun 16 Aug 2020 - 05:15:am (Sydney)

IMM Share Price

IMMUTEP LIMITEDIMMPharmaceuticals, Biotechnology & Life Sciences

IMM Company Information

Name:

Immutep Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

95 Pitt Street Sydney Australia 2000

Phone:

61 2 8315 7003

CEO, CFO, Chief Bus. Officer & Exec. Director:

Mr. Marc Voigt

COO, Gen. Counsel & Company Sec.:

Ms. Deanne Miller

Chief Scientific Officer & Chief Medical Officer:

Dr. Frédéric Triebel

Company Sec.:

Mr. Thomas Robert John Bloomfield

Director of Clinical Devel. & Regulatory Affairs:

Mr. Christian Mueller

Company Overview:

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP761 for autoimmune disease. It has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreements with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.; and partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.

IMM Share Price Information

Shares Issued:

388.80M

Market Capitalisation:

$69.98M

Revenue (TTM):

$12.95M

Revenue Per Share (TTM):

$0.04

Earnings per Share:

$-0.006

Profit Margin:

-1.2055

Operating Margin (TTM):

$-1.24

Return On Assets (TTM):

$-0.22

Return On Equity (TTM):

$-0.51

Quarterly Revenue Growth (YOY):

3.207

Gross Profit(TTM):

$-10,953,990

Diluted Earnings Per Share (TTM):

$-0.044

IMM CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-19,000

Dividends Paid:

$0

Capital Expenditures:

$19K

IMM Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-18,343,984

Net Income:

$-18,343,984

Gross Profit:

$-10,953,990

Operating Income:

$-18,962,415

Total Revenue:

$139.78K

Total Operating Expenses:

$19.10M

Cost Of Revenue:

$16.59M

IMM Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$16.84M

Total Liabilities:

$16.15M

Total Stockholder Equity:

$24.39M

Other Current Liabilities:

$2.50M

Total Assets:

$40.54M

Common Stock:

$211.43M

Other Current Assets:

$57.16K

Retained Earnings:

$-262,237,829

Other Liabilities:

$3.21M

Good Will:

$109.96K

Cash:

$16.57M

Total Current Liabilities:

$5.30M

Property - Plant & Equipment:

$52.95K

Net Tangible Assets:

$7.44M

Total Current Assets:

$23.54M

Long-Term Debt:

$7.64M

Net Receivables:

$4.93M

Short-Term Investments:

$17M

Accounts Payable:

$2.56M

Non Currrent Assets (Other):

$17M

Short-Term Investments:

$17

Non Current Liabilities Total:

$10.85M

IMM Share Price History

IMM News

11 Aug, 2020
SYDNEY, Australia, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 10,736,940) entitled “Combined Preparations for the Treatment of Cancer” by the United States Patent Office.This United States patent follows the grant of the corresponding European, Australian and Japanese patents (announced 23 May 2019, 21 June 2019 and 7 May 2020, respectively) and protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan.This new patent highlights the ongoing and important steps being taken by the Company to protect its lead product candidate in a range of novel and highly relevant combination formats, in both chemo-immunotherapy and other immunotherapy settings.The patent expiry date is 25 January 2035 (including 37 days of patent term adjustment).Further information can be found on the Company’s website www.immutep.com or by contacting:Australian Investors/Media: Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; cstrong@citadelmagnus.comU.S. Media: Tim McCarthy, LifeSci Advisors +1 (212) 915.2564; tim@lifesciadvisors.com
21 Jul, 2020
Immutep Limited (ASX:IMM) has rebounded strongly over the last week, with the share price soaring 45%. But don't envy...
15 Jul, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) * Altimmune Inc (NASDAQ: ALT) (priced its $115 million worth of common stock and pre-funded warrant offering) * Beigene Ltd (NASDAQ: BGNE) * Bicycle Therapeutics PLC (NASDAQ: BCYC) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Imv Inc (NASDAQ: IMV) (provided an update on its coronavirus vaccine program) * INmune Bio Inc (NASDAQ: INMB)( announced positive interim Phase 1b data for its Alzheimer's drug) * OncoSec Medical Inc (NASDAQ: ONCS) * Qiagen NV (NYSE: QGEN) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) (announced initiation of clinical study of its fostamatinib for treating COVID-19 pneumonia) * TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) * Vaxart Inc (NASDAQ: VXRT) * VBI Vaccines Inc (NASDAQ: VBIV)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) * Acorda Therapeutics Inc (NASDAQ: ACOR) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * BELLUS Health Inc (NASDAQ: BLU) * Brickell Biotech Inc (NASDAQ: BBI) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX)(IPO quiet period expired) * Genfit SA (NASDAQ: GNFT) * Gritstone Oncology Inc (NASDAQ: GRTS) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * INVENTIVA SA/ADR (NASDAQ: IVA) (IPOed Friday) * Iterum Therapeutics PLC (NASDAQ: ITRM) * NanoVibronix Inc (NASDAQ: NAOV) * Nkarta Inc (NASDAQ: NKTX) (IPOed Friday) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Poseida Therapeutics, Inc. (NASDAQ: PSTX) (IPOed Friday) * Recro Pharma Inc (NASDAQ: REPH) * Repare Therapeutics Inc (NASDAQ: RPTX)(sell-side coverage began following expiry of IPO quiet period; Morgan Stanley initiated coverage of shares with a Buy rating) * Royalty Pharma plc (NASDAQ: RPRX) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN)Stocks In Focus Moderna Publishes Positive Efficacy, Safety Data For Coronavirus Study, to Start Phase 3 Trial July 27 Moderna Inc (NASDAQ: MRNA) announced the publication in the New England Journal of Medicine detailed interim Phase 1 data for its mRNA-1273 vaccine candidate against the novel coronavirus, showing the vaccine candidate induced rapid and strong immune responses.The vaccine candidate induced binding antibodies to the full-length SARS-CoV-2 Spike protein in all participants after the first vaccination, with all participants seroconverting by Day 15, the company said."These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 µg in a prime and boost regimen as the optimal dose for the Phase 3 study," said Tal Zaks, Chief Medical Officer of Moderna.Moderna expects to commence the Phase 3 study on July 27.The stock climbed 16.07% to $87.10 in after-hours trading.Immutep Awarded Patent For Out-licensed Antibody IMMUTEP LTD/S ADR (NASDAQ: IMMP) said the U.S. Patent and Trade Mark Office has granted a patent entitled "Antibody molecules to LAG-3 and uses thereof," which is related to embodiments of LAG525, a humanized form of its IMP701 antibody which is out-licensed to Novartis AG (NYSE: NVS).The patent is co-owned by Novartis and Immutep and will expire on March 26, 2035.The stock skyrocketed 95.45% to $2.15 in after-hours trading.GlaxoSmithKline's Multiple Myeloma Treatment Candidate Unanimously Endorsed By FDA Panel GlaxoSmithKline plc (NYSE: GSK) said FDA's Oncologic Drugs Advisory Committee voted 12-0 in favor of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.The drug linker technology used has been licensed from Seattle Genetics, Inc. (NASDAQ: SGEN).ProQR Gets $30M Debt Funding That Extends Cash Runway Into 2023 ProQR Therapeutics NV (NASDAQ: PRQR) said it has clinched a $30 million convertible debt financing agreement with Pontifax Medison Debt Financing, the healthcare-dedicated venture and debt fund of the Pontifax life science funds."If fully drawn down, this capital would extend ProQR's cash runway into 2023, which is beyond a number of anticipated catalysts and value inflection points for our clinical stage programs," the company said in a statement.The company also said it expects the funding to accelerate advancement of its translational platform and discovery programs."The stock gained 10.77% to $5.45 in after-hours trading.Acorda Gets $12.7M Income Tax Refund From IRSAcorda said in an 8-K filing it received a $12.7 million income tax refund from the IRS including interest, pursuant to the Coronavirus Aid, Relief, and Economic Security Act. The provisions of the Act allowed the company to carry back 2019 net operating losses to tax years 2017 and 2018, resulting in the refund, it said.The stock jumped 31.43% to 96 cents in after-hours trading.J&J Gets Label Expansion For Psoriasis Drug Johnson & Johnson's (NYSE: JNJ) Janssen unit announced FDA approval of Tremfya as a treatment for adult patients living with active psoriatic arthritis.Tremfiya is a fully human monoclonal antibody generated utilizing Morphosys Ag's (NASDAQ: MOR) proprietary HuCAL antibody technology.Medtronic to Buy Spinal Implant Technology Company Medicrea Medtronic PLC (NYSE: MDT) announced a tender offer agreement for the acquisition of all outstanding shares of Medicrea International SA (OTC: MRNTF), which facilitates spinal surgery through artificial intelligence, predictive modeling and patient specific implants. The agreement values each of Medicrea shares at 7 euro.OfferingsZynex Inc. (NASDAQ: ZYXI) said it priced its previously announced underwritten public offering of an aggregate of 2.5 million shares at $22.00 per share. The company said it is selling 1.25 million shares, with the remaining 1.25 million shares being sold by certain stockholders. The company expects gross proceeds of $27.5 million from the shares sold by it.The stock slipped 7.67% to $24.21 in after-hours trading.Adaptive Biotechnologies Corp (NASDAQ: ADPT) announced the commencement of a proposed underwritten public offering of 8 million shares of its common, with 6 million shares being offered by the company and 2 million by a selling shareholder.In after-hours trading, the stock fell 2.64% to $42.11.On The Radar Adcom Meeting The Cardiovascular and Renal Drugs Advisory Committee is scheduled to discuss Mallinckrodt PLC's (NYSE: MNK) new drug application for terlipressin, lyophilized powder for solution for injection, for the proposed indication of treatment of hepatorenal syndrome Type 1.See more from Benzinga * The Daily Biotech Pulse: Blueprint, Roche Ink .7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits * Moderna Analyst: Coronavirus Vaccine Will Get Approved, Clock B+ In Orders Over Next Few Years * The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Relay Therapeutics IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
14 Jul, 2020
SYDNEY, Australia, July 15, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody.
29 Jun, 2020
Completes recruitment of patients with first line Non-Small Cell Lung Cancer (NSCLC)81 patients out of up to 109 now participating across the trial, with recruitment continuing.
22 Jun, 2020
SYDNEY, Australia, June 22, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate.
01 Jun, 2020
Shares in Immutep (IMMP) are surging 10% in Monday’s pre-market trading after the company announced first interim data from its ongoing INSIGHT-004 Phase I clinical trial at the 2020 American Society of Clinical Oncology’s (ASCO) Annual Meeting.The Frankfurt-based study is a phase I trial evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (“IMP321” or “efti”) with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialized by Merck KGaA (MRK), Darmstadt, Germany and Pfizer Inc (PFE).Patients in cohort 1 receive 6mg doses of efti every two weeks with the standard dose of avelumab (800mg every two weeks), while patients in cohort 2 receive a higher dose of efti, 30mg, with avelumab.According to the presentation, 33% of patients (4 out of 12) showed a partial response (PR) to the combination therapy. In cohort 2, 3 patients out of 6 have not yet had their response assessed but are still under therapy without clinical signs of tumour progression, the company said, while noting a number of encouraging single PR cases.INSIGHT-004 reached full recruitment in April 2020 and has recruited patients in different solid tumors, primarily with gastrointestinal indications. It is the first combination trial of an approved and marketed anti-PD-L1 drug and efti.Trial investigator, Prof Salah-Eddin Al-Batran, commented: “It is good to see a number of patients are responding to the combination therapy of efti and avelumab, particularly as three patients in cohort 2 are still very early on in their treatment and haven’t yet been assessed… These patients typically are heavily pretreated and do not have any good therapy options.”Interim results from the first cohort in the trial show that the combination treatment is well tolerated with no dose limiting toxicities, while safety data from the second cohort will be reported at a later date.Two analysts have recently published buy recommendations on IMMP, giving the stock a Moderate Buy analyst consensus. Meanwhile the average analyst price target of $3.50 indicates a further 184% lies ahead. (See IMMP stock analysis on TipRanks). Shares are currently trading down 31% year-to-date, after the company announced disappointing top-line data from the P2b AIPAC study in metastatic breast cancer (mBC).“Is all lost for Immutep? Not at all, in our view… The mBC data is a disappointment, but efti and the other LAG3s in the pipeline still have a path forward. Overall, in our view, the damage has been done to IMMP shares” wrote Maxim Group’s Jason McCarthy at the time.Related News: Adaptimmune Spikes 127% Post-ASCO; Analyst Triples Price Target Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Tesla CEO Elon Musk Sees Model Y Facing Production Challenges * Lululemon Earnings Preview: Will LULU Live Up To The Hype? * Tailored Brands Is Said To Weigh Bankruptcy Protection; Shares Fall In Pre-Market * Soleno Plunging 48% In Pre-Market On Obesity Study Failure
31 May, 2020
Presented at ASCO 2020 Annual Meeting First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC)Improving Overall Response Rate (iORR) in HNSCC,.
First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCOEncouraging early activity signals in a variety.
29 May, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)( announced a collaboration study for razuprotafib in COVID-19 treatment) * Aileron Therapeutics Inc (NASDAQ: ALRN) * Arca Biopharma Inc (NASDAQ: ABIO) ( reacted to its planned foray into COVID-19 treatment) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) * ChemoCentryx Inc (NASDAQ: CCXI) * GENMAB A/S/S ADR (NASDAQ: GMAB)(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) * Imara Inc NASDAQ: (IMRA) * Liquidia Technologies Inc (NASDAQ: LQDA) * Mersana Therapeutics Inc (NASDAQ: MRSN) * Protagonist Therapeutics Inc (NASDAQ: PTGX) * Qiagen NV (NYSE: QGEN) * Tenax Therapeutics Inc (NASDAQ: TENX) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * Vermillion, Inc. (NASDAQ: VRML)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 28) * Zafgen Inc (NASDAQ: ZFGN)Stocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients. The data is to be presented at the ASCO 2020 Virtual Scientific Program.The SVd arm, according to the company, showed a statistically significant increase of 47% in median progression-free survival compared to the Vd arm. The overall response rate was 76.4% for the SVd arm compared to 62.3% for the Vd arm.The stock rose 7.71% to $20.25 in after-hours trading.Eisai, Merck Announce ASCO Presentations Eisai Co., Ltd (OTC: ESALY) and Merck & Co., Inc. (NYSE: MRK) said results from two trials evaluating the former's Lenvima, plus the latter's anti-PD-1 therapy Keytruda in patients with unresectable hepatocellular carcinoma, or HCC, with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma, or ccRCC, who progressed following immune checkpoint inhibitor therapy, respectively, showed tumor response.The data is to be presented at the ASCO Virtual Scientific Program.Separately, Merck said a Phase 3 trial, dubbed KEYNOTE-177, evaluating Keytruda for the first-line treatment of patients with microsatellite instability-high, or MSI-H, or mismatch repair deficient, or dMMR, unresectable or metastatic colorectal cancer showed Keytruda significantly reduced the risk of disease progression or death by 40%, with a median progression-free survival of 16.5 months compared with 8.2 months for patients treated with chemotherapy, a current standard of care.Merck said the data is scheduled to be presented Sunday in the ASCO meeting.Altimmune Shares Rally On Insider Buying Altimmune Inc (NASDAQ: ALT) shares were rallying after Venrock Healthcare Capital Partners III filed with the SEC in Form 4 a series of purchases made over this week that has taken its holdings to 3 million shares. A total of 1.304 million shares were accumulated over the week.Immutep Gets $2.41M In R&D Tax Incentive From French Government IMMUTEP LTD/S ADR (NASDAQ: IMMP) said it has received a 2.174-million euro or $2.41 million, R&D tax incentive payment in cash from the French government. The tax credit is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761, the company said.In after-hours trading, the stock added 2.40% to $1.28.Roche's Cancer Drug Gets Positive European Medicines Agency Committee Recommendation Roche Holdings AG (OTC: RHHBY) said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion under conditional marketing authorization for Rozlytrek for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase gene fusion. The CHMP has also recommended Rozlytrek for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer not previously treated with ROS1 inhibitors.Offerings Marinus Pharmaceuticals Inc (NASDAQ: MRNS) priced its underwritten public offering of 16 million shares at $2.50 per share, for generating gross proceeds of about $40 million. The company expects the offering to close on or about June 2.The stock slid 8.21% to $2.57 in after-hours trading.On The Radar Several companies are scheduled to present data on their pipeline assets in the ASCO 2020 Annual Meeting Virtual Scientific Program. Some of the companies presenting Friday include:• Arvinas Inc (NASDAQ: ARVN) • Trillium Therapeutics Inc (NASDAQ: TRIL) Cardiff Oncology Inc (NASDAQ: CRDF) • Iovance Biotherapeutics Inc (NASDAQ: IOVA) • Blueprint Medicines Corp (NASDAQ: BPMC) • Allogene Therapeutics Inc (NASDAQ: ALLO) • Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) • GENMAB A/S/S ADR (NASDAQ: GMAB) • AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) • Amgen, Inc. (NASDAQ: AMGN) • Clovis Oncology Inc (NASDAQ: CLVS) • IMMUTEP LTD/S ADR (NASDAQ: IMMP) • Heat Biologics Inc (NASDAQ: HTBX) • Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) • Oncolytics Biotech, Inc. (NASDAQ: ONCY) • Athenex Inc (NASDAQ: ATNX) • Harpoon Therapeutics Inc (NASDAQ: HARP) • Gossamer Bio Inc (NASDAQ: GOSS) • ImmunoGen, Inc (NASDAQ: IMGN) • Merus NV (NASDAQ: MRUS) • CytomX Therapeutics Inc (NASDAQ: CTMX) • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) • Pfizer Inc. (NYSE: PFE) • CELYAD SA/ADR (NASDAQ: CYAD) • Immunomedics, Inc. (NASDAQ: IMMU) • Xencor Inc (NASDAQ: XNCR) • MacroGenics Inc (NASDAQ: MGNX) • DelMar Pharmaceuticals Inc (NASDAQ: DMPI) • Salarius Pharmaceuticals Inc (NASDAQ: SLRX) • AstraZeneca plc (NYSE: AZN) • Genocea Biosciences Inc (NASDAQ: GNCA) • NextCure Inc (NASDAQ: NXTC) • Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH) • Adaptimmune Therapeutics PLC (NASDAQ: ADAP) • ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) • Agios Pharmaceuticals Inc (NASDAQ: AGIO) • Oncternal Therapeutics Inc (NASDAQ: ONCT) • Roche • Aptose Biosciences Inc (NASDAQ: APTO) • Kura Oncology Inc (NASDAQ: KURA) • Innate Pharma SA (NASDAQ: IPHA) • Imv Inc (NASDAQ: IMV): • MEI Pharma Inc (NASDAQ: MEIP) • TapImmune Inc. common stock (NASDAQ: MRKR) • Inovio Pharmaceuticals Inc (NASDAQ: INO)See more from Benzinga * The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas * Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SYDNEY, Australia, May 29, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
28 May, 2020
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
27 May, 2020
SYDNEY, Australia, May 27, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST).
30 Apr, 2020
SYDNEY, Australia, April 30, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two.
28 Apr, 2020
Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC):    º Improving Overall Response Rate (ORR) of 53% (earlier data indicated 47%)    º.
23 Apr, 2020
Immutep Limited's (ASX:IMM): Immutep Limited, a biotechnology company, engages in the research, development, and...
22 Apr, 2020
SYDNEY, Australia, April 22, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.
16 Apr, 2020
SYDNEY, Australia, April 16, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing.
14 Apr, 2020
SYDNEY, Australia, April 14, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.
08 Apr, 2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing efti (designated as EOC202 in China) in metastatic breast cancer. The confirmation follows EOC Pharma’s analysis of the recently reported Progression Free Survival (PFS) data, including subgroup analysis, from Immutep’s phase IIb AIPAC study.